Sanofi SA (EPA:SAN) Given Average Recommendation of “Buy” by Brokerages

Share on StockTwits

Shares of Sanofi SA (EPA:SAN) have received a consensus rating of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is €98.35 ($114.36).

A number of equities research analysts have recently issued reports on SAN shares. Morgan Stanley set a €105.00 ($122.09) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Tuesday, February 4th. Goldman Sachs Group set a €100.00 ($116.28) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Thursday, February 6th. Sanford C. Bernstein set a €100.00 ($116.28) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Friday, February 7th. Kepler Capital Markets set a €99.00 ($115.12) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Monday, February 10th. Finally, UBS Group set a €89.50 ($104.07) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Thursday, February 6th.

Sanofi stock opened at €92.24 ($107.26) on Friday. Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10). The company has a fifty day simple moving average of €90.73 and a 200-day simple moving average of €83.67.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: FTSE 100 Index

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.